CCL3 and neoplasm: In the present study, we demonstrated that F4/80-B220-CD11c+ DC precursors mobilized by CCL3 and CCL20 can induce tumor-specific CTL and elicit potent, therapeutic effects against solid and metastatic tumors when modified with MAGE-1.